Literature DB >> 6420216

Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism.

U P Steinbrecher, J L Witztum.   

Abstract

In previous studies we have shown that extensive glucosylation of low-density lipoproteins (LDL) (40% of lysines modified) completely blocks receptor-mediated degradation in animals and in man. Other studies indicated that in some diabetics up to 5% of lysine residues of LDL were glucosylated. The present study was done to determine if the extent of glucosylation of LDL which can occur in diabetics could alter LDL catabolism. We measured degradation by cultured normal human fibroblasts and turnover in guinea pigs of various LDLs with 2-17% of lysine residues glucosylated. Modification of as few as 2-5% of lysines decreased LDL catabolism by 5-25%, and the degree of inhibition of catabolism was linearly related to the extent of LDL glucosylation. These results indicate that the extent of LDL glucosylation that can occur in diabetes may slow LDL catabolism and hence increase plasma LDL levels.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6420216     DOI: 10.2337/diab.33.2.130

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  40 in total

Review 1.  The chronic cardiovascular risk factor syndrome (syndrome X): mechanisms and implications for atherogenesis.

Authors:  S C Bain; P M Dodson
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

Review 2.  Lipoprotein alterations in diabetes mellitus.

Authors:  G M Kostner; I Karádi
Journal:  Diabetologia       Date:  1988-10       Impact factor: 10.122

Review 3.  Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms.

Authors:  Alin Stirban; Thomas Gawlowski; Michael Roden
Journal:  Mol Metab       Date:  2013-12-07       Impact factor: 7.422

4.  Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine.

Authors:  Ayelet Gonen; Lotte F Hansen; William W Turner; Erica N Montano; Xuchu Que; Apaїs Rafia; Meng-Yun Chou; Philipp Wiesner; Dimitrios Tsiantoulas; Maripat Corr; Michael S VanNieuwenhze; Sotirios Tsimikas; Christoph J Binder; Joseph L Witztum; Karsten Hartvigsen
Journal:  J Lipid Res       Date:  2014-08-20       Impact factor: 5.922

5.  Relationship between lipid profiles and kidney function in patients with type 1 diabetes.

Authors:  N Tolonen; C Forsblom; L Thorn; J Wadén; M Rosengård-Bärlund; M Saraheimo; O Heikkilä; K Pettersson-Fernholm; M-R Taskinen; P-H Groop
Journal:  Diabetologia       Date:  2007-11-10       Impact factor: 10.122

Review 6.  The effects of antihypertensive drugs on serum lipids and lipoproteins, I. Diuretics.

Authors:  R P Ames
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

7.  Glucose oxidation and low-density lipoprotein-induced macrophage ceroid accumulation: possible implications for diabetic atherosclerosis.

Authors:  J V Hunt; M A Bottoms; K Clare; J T Skamarauskas; M J Mitchinson
Journal:  Biochem J       Date:  1994-05-15       Impact factor: 3.857

8.  Glycated LDL increases monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated chemotaxis.

Authors:  Kikuo Isoda; Eduardo Folco; M Reza Marwali; Fumitaka Ohsuzu; Peter Libby
Journal:  Atherosclerosis       Date:  2007-12-27       Impact factor: 5.162

9.  Conformational changes induced in lens alpha- and gamma-crystallins by modification with glucose 6-phosphate. Implications for cataract.

Authors:  H T Beswick; J J Harding
Journal:  Biochem J       Date:  1987-09-15       Impact factor: 3.857

10.  Inhibiting low-density lipoprotein glycation ameliorates increased cholesteryl ester synthesis in macrophages and hypercholesterolemia and aortic lipid peroxidation in streptozotocin diabetic rats.

Authors:  Margo P Cohen; Elizabeth A Shea; Van-Yu Wu
Journal:  Metabolism       Date:  2009-11-18       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.